A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

Autor: Luigi Coltelli, Giacomo Allegrini, Paola Orlandi, Chiara Finale, Andrea Fontana, Luna Chiara Masini, Marco Scalese, Giada Arrighi, Maria Teresa Barletta, Ermelinda De Maio, Marta Banchi, Elisabetta Fini, Patrizia Guidi, Giada Frenzilli, Sara Donati, Simona Giovannelli, Lucia Tanganelli, Barbara Salvadori, Lorenzo Livi, Icro Meattini, Ilaria Pazzagli, Marco Di Lieto, Mirco Pistelli, Virginia Casadei, Antonella Ferro, Samanta Cupini, Francesca Orlandi, Damiana Francesca, Giulia Lorenzini, Leonardo Barellini, Alfredo Falcone, Alessandro Cosimi, Guido Bocci

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-9 (2022)

Abstract To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1α, EPAS-1, and TSP-1 SNPs and their role on progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with bevacizumab plus first-line pa

Externí odkaz: https://doaj.org/article/ddb3a8574ac74c6f9118cd6ec4935bea

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Autor: Emanuela Rossi, Francesca Di Rella, Carlo Putzu, Francesco Perrone, Rossella Lauria, Lucia Del Mastro, Gennaro Daniele, Vittorio Simeon, Vincenza Tinessa, Ermelinda De Maio, Sabino De Placido, G. Landi, Sandro Barni, Francesco Nuzzo, Saverio Cinieri, Giovanni Iodice, Andrea de Matteis, Nicola Normanno, A. Fabbri, Carmen Pacilio, Laura Arenare, Maria Carmela Piccirillo, Toni Ibrahim, Valeria Forestieri, Angela Stefania Ribecco, Adriano Gravina, Ciro Gallo, Stefania Gori, Anna Maria Mosconi, Ferdinando Riccardi, Michele Orditura, Michelino De Laurentiis

Publikováno v: European journal of cancer (Oxford, England : 1990). 118

Aim The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor–positive (HR+) tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16989de51f471ccf27840bdb59d88cf2
https://pubmed.ncbi.nlm.nih.gov/31374402

Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly

Autor: Francesco Perrone, Gaetano Capuano, Giuseppe Signoriello, Luigi Elio Adinolfi, Maria Stanzione, Carlo Del Naja, Giampiero Marone, Silvana Elba, Fabio Farinati, Francesco Izzo, Sandro Pignata, Antonio Giorgio, Fabiana Castiglione, Massimo Di Maio, Ermelinda De Maio, Ilario de Sio, Ciro Gallo, Oreste Cuomo, Giovanni Battista Gaeta, Martina Felder, Bruno Daniele

Publikováno v: Critical Reviews in Oncology/Hematology. 59:243-249

Purpose To describe the characteristics at presentation and the outcome of elderly patients (≥70 years old) with HCC, a retrospective analysis using a CLIP database was performed. Patients and methods The database included 650 patients. χ 2-test,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19b5d25d9b6e5f6a326f1c31d852ad3c
https://doi.org/10.1016/j.critrevonc.2006.01.002

Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial

Autor: Gridelli C., Gallo C., Morabito A., Iaffaioli R. V., Favaretto A., Isa L., Barbera S., Gamucci T., Ceribelli A., Filipazzi V., Maione P., Rossi A., Barletta E., Signoriello S., De Maio E., Piccirillo M. C., Di Maio M., Rocco G., Vecchione A., Perrone F., Cesare Gridelli, Paolo Maione, Antonio Rossi, Ciro Gallo, Giuseppe Signoriello, Paolo Chiodini, Simona Signoriello, Francesco Perrone, Massimo Di Maio, Maria Carmela Piccirillo, Ermelinda De Maio, Jane Bryce, Alessandro Morabito, Raffaele Costanzo, Gaetano Rocco, Rosario Vincenzo Iaffaioli, Emiddio Barletta, Roberta Formato, Aldo Vecchione, Adolfo Favaretto, Giulia Pasello, Cristina Magro, Luciano Isa, Raffaele Venezia, Mario Comandè, Santi Barbera, Francesco Renda, Antonio Volpintesta, Teresa Gamucci, Maria Anna Giampaolo, Giovanni Mansueto, Anna Ceribelli, Ilaria Carbone, Domenica Pellegrini, Virginio Filipazzi, Elena Piazza, Sabrina Ferrario, Vittorina Zagonel, Giuditta di Isernia, Marco Ciaparrone, Francovito Piantedosi, Fabiana Vitiello, Nicolò Borsellino, Maria Elia Vitale, Luigi Brancaccio, Sergio Spina, Maria Rosaria Valerio, Raffaella Felletti, Salvatore Tafuto, Marianna Giampaglia, Rita Migliorino, Francesco Rosetti, Francesco Carrozza, Nestore Rossi, Mario Spatafora, Manlio Mencoboni, Ernest Marshall

Introduction: Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence. Methods: Patients with extensive SCLC, age >70 years, and performance status 0-2 were eligible for a study looking for optimal two-drug combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c287ad1d0d718db86daca9f97723eed4
http://hdl.handle.net/2318/150674

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

Autor: Angelo Antonio Mastro, Giuseppe D'Aiuto, Emanuela Rossi, Vincenzo Labonia, Gabriella Landi, Andrea de Matteis, Ermelinda De Maio, Gerardo Botti, Francesco Nuzzo, Francesco Perrone

Publikováno v: Cancer. 94:895-901

BACKGROUND The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2d1a50b27aff8b0d19705fd38d7ca5
https://doi.org/10.1002/cncr.20335